Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.

119th Congress Introduced by Becca Balint and 49 co-sponsors

Declares mifepristone safe and effective and urges policy to be science-based, equitable, and transparent in access to time-sensitive medication abortion.

Submitted in House

Overview

House Resolution 1285 (HRES 1285), introduced in the 119th Congress, expresses the sense of the House of Representatives regarding the safety, effectiveness, and accessibility of mifepristone, a medication used for abortion care. The resolution emphasizes that more than 25 years of real-world evidence and hundreds of peer-reviewed studies support mifepristone’s safety and effectiveness, and it calls for law and policy governing access to this time-sensitive medication abortion care to be equitable, transparent, and science-based. The measure is non-binding and reflects a congressional statement of priorities rather than new law.

Purpose and Intent

Acknowledges and affirms the safety and effectiveness of mifepristone based on decades of real-world experience and peer-reviewed research.

Urges that laws, regulations, and policies governing access to mifepristone be aligned with the best available scientific evidence.

Calls for approaches to medication abortion access that are equitable and transparent, reducing barriers and ensuring timely care.

Key Provisions

As a House Resolution, HRES 1285 does not enact new statutory requirements or create enforceable federal programs. Instead, its core elements are:

A statement of support for mifepristone’s safety and efficacy, citing more than 25 years of evidence.

A call for policy and regulatory frameworks to reflect science-based, evidence-informed decisionmaking.

Emphasis on ensuring access to time-sensitive medication abortion in a manner that is fair and transparent.

Who/What Is Affected

The resolution signals congressional intent to influence how federal, state, and possibly local policies consider mifepristone access.

It may affect policymakers, healthcare providers, patients seeking medication abortion, and organizations involved in reproductive health policy by signaling support for evidence-based practices.

Procedural and Timeline Aspects

Action History: On May 14, 2026, HRES 1285 was referred to the House Committee on Energy and Commerce and was submitted in the House.

Next steps (typical for such resolutions): committee consideration, potential markup, and floor consideration. As a non-binding sense-of-the-House measure, it does not become law but can guide legislative priorities and influence ongoing policy debates.

Potential Impact

Sets a formal legislative position favoring science-based access to mifepristone.

Could shape the framing of future regulations, oversight, and funding decisions related to medication abortion.

Signals bipartisan or cross-partisan interest in aligning policy with substantial medical evidence, potentially affecting regulatory discussions at agencies overseeing reproductive health care.

If you’d like, I can add context comparing this resolution to prior related measures or outline potential policy avenues it could influence (e.g., FDA-related guidance, state-access regulations, or access programs).